Veteran US E-Commerce Entrepreneur Frank Poore to join Board of ENGAGE XR
US e-commerce entrepreneur, and founder and CEO of CommerceHub, Frank Poore has been appointed as a Non-executive Director of leading virtual reality ('VR') technology company, ENGAGE XR Holdings plc (“ENGAGE XR”).
Frank brings a wealth of entrepreneurial and business experience to ENGAGE XR with over 25 years as an e-commerce innovator and visionary. As founder and CEO of CommerceHub, Frank built an industry-leading company that enables $30 billion in recurring e-commerce sales for 15,000 of the world’s largest retailers, brands, distributors, and marketplaces.
Based in Europe, ENGAGE XR (which is changing its name from VR Education Holdings plc) is listed on the London Stock Exchange. ENGAGE XR is focused on becoming a leading global provider of virtual communications solutions through its proprietary software platform, ENGAGE. ENGAGE provides users with a platform for creating, sharing, and delivering VR content for communication, training, and online events. The Company has announced the development of a new fully featured corporate metaverse, codenamed "ENGAGE Oasis", with the launch expected in the first half of 2022.
In the first six months of 2021, the Company’s revenue increased by 83% to €1.25 million as demand for VR as a communications tool, was accelerated by the pandemic. Since ENGAGE’s launch in 2019, the number of commercial customers has increased to over 130, as well as the Company making significant progress in the roll-out of ENGAGE in China through its partnership with HTC and entering the Middle East for the first time. ENGAGE customers include Abbott Laboratories, BMW Motorsport, Facebook, HTC, MongoDB, and the US State Department.
As well as serving on the Board, Frank will work with the management of ENGAGE XR to help expand the Company’s sales function to help achieve its goal of becoming a leading global provider of virtual communications and support the successful roll-out of ENGAGE Oasis.
As CEO, Frank led CommerceHub through enormous periods of growth, resulting in major milestone events including international expansion, two significant acquisitions, and a successful public floatation on Nasdaq. CommerceHub’s platform and business model were also highly respected for generating industry-leading EBITDA returns. Frank created four successful liquidity events for CommerceHub shareholders - first through a sale of CommerceHub to QVC/Comcast Corporation in 2006, second via public offering in 2016 on Nasdaq, third through a $1 billion take-private sale of CommerceHub to GTCR and Sycamore Partners in 2018, and most recently through a majority sale to Insight Partners and Goldman Sachs for nearly $2 billion in December 2020.
David Whelan, CEO of ENGAGE XR, commented: “With over 25 years’ experience as a successful entrepreneur, building a company with a strong sales and technology focus, and a track record of delivering value for global multinational businesses, Frank is a major addition to our Board. His experience will be invaluable as we expand our ENGAGE metaverse offering particularly in North America working together to achieve our ambitious medium and long-term growth targets.”
Frank Poore said: “I am excited to join the Board of VRE and to work with VR pioneers like David and Sandra. As companies embrace remote work, they will need new ways to manage their culture and team chemistry. ENGAGE is already well-positioned as the “office of the future” by enabling distributed teams to come together into a virtual office, conference room, auditorium, classroom, or coffee shop to create a sense of presence and to foster collaboration, creativity, and serendipity. The development of ENGAGE Oasis is especially exciting and it can establish itself as the go-to virtual world where global organizations come to interact with each other, and their stakeholders. I believe that my background and personality will bring a disruptive yet collaborative spirit that can help unlock substantial value for shareholders.”
Website: https://www.engagexrholdings.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005833/en/
Contact information
SEC Newgate
Robin Tozer / Isabelle Smurfit
VReducation@secnewgate.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
